Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05105477 · ClinicalTrials.gov registry record · NA
Hypotension Prediction Index (HPI) SMART-BP Trial
A NA study, sponsored by Edwards Lifesciences.
- Terminated
- Registry status
- NA
- Development phase
- 407
- Enrollment target
NCT05105477 is a NA study that was terminated before completion, run by Edwards Lifesciences. The registered enrollment target is 407 participants.
The verdict
NCT05105477, a NA study, was terminated before completion, sponsored by Edwards Lifesciences.
- TERMINATED
- Registry status
- NA
- Development phase
- 407 participants
- Enrollment target
Study Summary
A multicenter, randomized comparison of intraoperative hemodynamic management with or without a protocolized strategy utilizing Hypotension Prediction Index (HPI) software guidance during moderate-to-high-risk noncardiac surgery.
Interventions
- DEVICE AcumenTM HPI Software Feature
- OTHER Non-protocolized Standard of Care
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 407 participants |
| Start Date | 2021-11-17 |
| Est. Completion | 2022-12-15 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05105477
The ClinicalTrials.gov registry entry for NCT05105477 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 407 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Edwards Lifesciences, which has 57 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which AcumenTM HPI Software Feature is the first listed.
NCT05105477 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05105477 about?
NCT05105477 is a clinical study titled "Hypotension Prediction Index (HPI) SMART-BP Trial". A multicenter, randomized comparison of intraoperative hemodynamic management with or without a protocolized strategy utilizing Hypotension Prediction Index (HPI) software guidance during moderate-to-high-risk noncardiac surgery.
What is the current status of trial NCT05105477?
This trial is currently terminated. It is a NA study. The enrollment target is 407 participants. The study started on 2021-11-17. Estimated completion is 2022-12-15.
What interventions are being tested in trial NCT05105477?
The interventions under investigation include: AcumenTM HPI Software Feature (DEVICE), Non-protocolized Standard of Care (OTHER).
Who is sponsoring clinical trial NCT05105477?
This trial is sponsored by Edwards Lifesciences, which has 57 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.